GlassScriptPhysician profile
Michael J Dao
NPI 1033182951
$50,139.16
in general payments reported to CMS, 2019-2025
64 companies · $8,567 in 2025
The $8,567 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,207 · 2020: $3,541 · 2021: $6,259 · 2022: $6,486 · 2023: $7,284 · 2024: $8,796 · 2025: $8,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25K · Education: $24.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24,621.96 |
| Education | $24.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,341.32 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $6,846.94 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $4,817.48 | 2019-2025 | Vraylar, Linzess, Qulipta |
| Glaxosmithkline, LLC. | $3,706.05 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Janssen Pharmaceuticals, INC | $3,420.94 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,908.48 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $2,662.16 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $2,340.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $1,669.87 | 2019-2025 | Epclusa, Vemlidy |
| Allergan, INC. | $1,464.07 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $815.87 | 2021-2025 | |
| Amarin Pharma, INC. | $778.67 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $772.02 | 2019-2025 | Verquvo, Capvaxive, Vaxneuvance |
| Phathom Pharmaceuticals, INC. | $721.24 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $710.79 | 2020-2023 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $628.22 | 2024-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $515.38 | 2019-2025 | Linzess |
| Radius Health, INC. | $500.52 | 2019-2024 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $464.48 | 2019-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $413.01 | 2024-2025 | Fanapt |
| Abbott Laboratories | $395.04 | 2023-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $388.07 | 2019-2025 | |
| Corcept Therapeutics | $366.79 | 2023-2024 | Korlym |
| Aimmune Therapeutics, INC. | $347.78 | 2024-2025 | Zenpep |
| Insulet Corporation | $346.59 | 2025 | Omnipod |
| Cequr Corporation | $326.11 | 2022-2025 | Cequr Simplicity |
| Abiomed | $296.18 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $251.02 | 2021 | |
| Pfizer INC. | $250.85 | 2019-2024 | |
| Axsome Therapeutics, INC. | $246.84 | 2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $237.20 | 2023 | Recorlev, Gvoke Hypopen |
| Intercept Pharmaceuticals, INC. | $233.98 | 2019-2023 | Ocaliva |
| Dexcom, INC. | $233.52 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $213.81 | 2025 | Myfembree, Gemtesa |
| Paratek Pharmaceuticals, INC. | $190.16 | 2023-2025 | Nuzyra |
| Exact Sciences Corporation | $185.13 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bard Peripheral Vascular, INC. | $172.81 | 2022 | |
| Genzyme Corporation | $162.61 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $154.53 | 2024 | Rexulti |
| Edwards Lifesciences Corporation | $151.67 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Eisai INC. | $145.82 | 2025 | |
| Redhill Biopharma INC. | $143.98 | 2024 | Talicia |
| Biohaven Pharmaceutical Holding Company LTD. | $138.49 | 2022 | |
| Lundbeck LLC | $124.23 | 2023-2025 | Rexulti |
| Lexicon Pharmaceuticals, INC. | $115.52 | 2023 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $86.12 | 2024-2025 | Zoryve |
| Ucb, INC. | $79.22 | 2021 | |
| Tolmar, INC. | $76.07 | 2025 | Jatenzo |
| Janssen Biotech, INC. | $67.54 | 2019 | |
| Baxter Healthcare | $61.41 | 2023-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Avion Pharmaceuticals | $60.61 | 2020-2021 | |
| Ibsa Pharma INC. | $57.58 | 2022 | |
| Sanofi-Aventis U.S. LLC | $55.62 | 2020-2021 | |
| Medtronic, INC. | $53.89 | 2024 | Minimed 780g |
| Optinose US, INC. | $47.39 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.83 | 2021 | |
| Zimmer Biomet Holdings, INC. | $40.14 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Oyster Point Pharma, INC. | $20.36 | 2023 | Tyrvaya |
| Revance Therapeutics, INC. | $19.70 | 2024 | Daxxify |
| Mylan Specialty L.P. | $17.59 | 2021 | |
| Genentech USA, INC. | $16.68 | 2019 | |
| Antares Pharma, INC. | $15.76 | 2025 | Xyosted |
| Intra-Sana Laboratories | $3.28 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.